Experts predict US-approved fezolinetant can be a ‘blockbuster’ for thousands of women in the UK
Menopause treatments will be revolutionised by a drug that acts directly on the brain to prevent hot flushes, leading doctors have predicted.
Speaking after the US approved the first non-hormonal menopause drug, made by Astellas Pharma, experts said the treatment could be transformative for the hundreds of thousands of women in the UK for whom hormone replacement drugs (HRT) are not suitable. The drug, fezolinetant, was licensed in the US on 12 May and could be approved for use in the UK by the end of the year.
